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Abstract
Objective:  To  review  the  literature  addressing  the  relationship  of  growth  and  nutritional  param-
eters with  pulmonary  function  in  pediatric  patients  with  cystic  ﬁbrosis.
Data source:  A  collection  of  articles  published  in  the  last  15  years  in  English,  Portuguese  and
Spanish was  made  by  research  in  electronic  databases  --  PubMed,  Cochrane,  Medline,  Lilacs
and Scielo  --  using  the  keywords  cystic  ﬁbrosis,  growth,  nutrition,  pulmonary  function  in  var-
ied combinations.  Articles  that  addressed  the  long  term  association  of  growth  and  nutritional
parameters,  with  an  emphasis  on  growth,  with  pulmonary  disease  in  cystic  ﬁbrosis,  were
included,  and  we  excluded  those  that  addressing  only  the  relationship  between  nutritional
parameters  and  cystic  ﬁbrosis  and  those  in  which  the  aim  was  to  describe  the  disease.
Data synthesis: Seven  studies  were  included,  with  a  total  of  12,455  patients.  Six  studies
reported relationship  between  growth  parameters  and  lung  function,  including  one  study
addressing  the  association  of  growth  parameters,  solely,  with  lung  function,  and  all  the  seven
studies reported  relationship  between  nutritional  parameters  and  lung  function.
Conclusions:  The  review  suggests  that  the  severity  of  the  lung  disease,  determined  by  spirome-
try, is  associated  with  body  growth  and  nutritional  status  in  cystic  ﬁbrosis.  Thus,  the  intervention
in these  parameters  can  lead  to  the  better  prognosis  and  life  expectancy  for  cystic  ﬁbrosis
patients.
© 2016  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY  license  (http://creativecommons.org/licenses/by/4.0/).
∗ Corresponding author.
E-mail: renanmauch@gmail.com (R.M. Mauch).
http://dx.doi.org/10.1016/j.rppede.2016.02.001
2359-3482/© 2016 Sociedade de Pediatria de Sa˜o Paulo. Published by Elsevier Editora Ltda. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
504  Mauch  RM  et  al.
PALAVRAS-CHAVE
Fibrose  cística;
Pulmão/ﬁsiopatologia;
Crescimento;
Nutric¸ão
Associac¸ão  dos  parâmetros  de  crescimento  e  nutricionais  com  func¸ão  pulmonar
na  ﬁbrose  cística:  revisão  da  literatura
Resumo
Objetivo:  Revisar  a  literatura  que  aborda  a  relac¸ão  entre  os  parâmetros  de  crescimento  e
nutricionais  com  a  func¸ão  pulmonar  em  pacientes  pediátricos  com  ﬁbrose  cística.
Fontes de  dados: Dados  foram  coletados  de  artigos  publicados  nos  últimos  15  anos  em  Inglês,
Português  e  Espanhol  através  de  pesquisa  nas  bases  de  dados  eletrônicas  --  PubMed,  Cochrane,
Medline, Lilacs  e  Scielo  --  usando  as  palavras-chave:  ﬁbrose  cística,  crescimento,  nutric¸ão,
func¸ão pulmonar  utilizando  combinac¸ões  variadas.  Os  artigos  que  analisaram  a  associac¸ão  de
longo prazo  entre  parâmetros  de  crescimento  e  nutricionais,  com  ênfase  em  crescimento,  com
doenc¸a pulmonar  em  ﬁbrose  cística,  foram  incluídos,  sendo  excluídos  aqueles  que  analisaram
apenas a  relac¸ão  entre  os  parâmetros  nutricionais  e  ﬁbrose  cística  e  aqueles  em  que  o  objetivo
era descrever  a  doenc¸a.
Síntese  dos  dados:  Sete  estudos  foram  incluídos,  com  um  total  de  12.455  pacientes.  Seis  estu-
dos relataram  relac¸ão  entre  parâmetros  de  crescimento  e  func¸ão  pulmonar,  incluindo  um  estudo
que analisou  apenas  a  associac¸ão  de  parâmetros  de  crescimento  com  a  func¸ão  pulmonar,  e  todos
os sete  estudos  relataram  associac¸ão  entre  parâmetros  nutricionais  e  func¸ão  pulmonar.
Conclusões:  A  revisão  sugere  que  a  gravidade  da  doenc¸a  pulmonar,  determinada  por  espirome-
tria, está  associada  com  crescimento  corporal  e  o  estado  nutricional  em  ﬁbrose  cística.  Assim,
a intervenc¸ão  nesses  parâmetros  pode  contribuir  para  um  melhor  prognóstico  e  expectativa  de
vida em  pacientes  com  ﬁbrose  cística.
© 2016  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Publicado  por  Elsevier  Editora  Ltda.  Este e´ um
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ystic  Fibrosis  (CF)  is  the  most  common  lethal  genetic  dis-
ase  in  Caucasian  populations.  It  is  caused  by  a  mutation
n  a  gene  that  encodes  the  Cystic  Fibrosis  Transmembrane
onductance  Regulator  (CFTR)  protein,  which  is  expressed
n  many  epithelial  and  blood  cells,  functioning  mainly  as
 chloride  channel.1 Pulmonary  disease  is  the  most  impor-
ant  manifestation  in  CF  and  the  main  factor  acting  in
orbidity  and  mortality  of  the  disease.  The  response  in
ulmonary  disease  is  mediated  by  abnormal  CFTR,2 modi-
er  genes,3--8 airway  infections  and  inﬂammation,9 probably
ffecting  weight  and  height  due  to  appetite  suppression  and
nhanced  energy  expenditure.
Malnutrition  and  growth  restriction  are  also  frequent  and
re  related  to  the  impairment  of  the  pulmonary  function  in
 vicious  circle:  malnourished  patients  tend  to  present  worst
ulmonary  function  and  patients  with  severe  pulmonary  dis-
ase  tend  to  grow  up  less.  Although  these  relationships  have
een  already  reported,10,11 there  are  a  few  long  term  anal-
ses  in  regard  to  the  achievement  of  growth  and  nutrition
oals  for  the  course  of  pulmonary  function  from  infancy  to
dulthood.
In  this  context,  the  aim  of  this  study  was  to  analyze  long
erm  studies  comparing  growth  and  nutrition  parameters
with  emphasis  in  growth)  with  pulmonary  function  in  CF
atients,  evaluating  the  relationship  among  these  factors.
ethod literature  review  of  the  last  15  years  (2000--2015)  about
he  relationship  between  growth  and  nutritional  parame-
ers  and  lung  function  was  made.  The  search  for  references
n  English,  Spanish  and  Portuguese  was  performed  through
A
s
wnc¸a  CC  BY  (http://creativecommons.org/licenses/by/4.0/).
lectronic  databases  --  PubMed,  Medline,  Cochrane,  Lilacs
nd  Scielo  --  using  the  descriptors:  CF,  growth,  body  growth,
ulmonary  function  and  lung  function  in  varied  combina-
ions  and  in  their  correspondent  translations  to  Portuguese
nd  Spanish.  Reviews  addressing  the  theme  were  also  con-
ulted,  as  well  reference  lists  of  all  articles,  to  search  for
ew  studies.
After  this  stage,  we  started  the  screening  of  papers,
y  analyzing  titles  and  abstracts.  The  ﬁrst  inclusion  crite-
ion  was  the  identiﬁcation  of  potentially  relevant  studies,
onsidering  those  in  which  the  report  compared  growth
arameters  with  lung  function.  In  this  case,  we  excluded
tudies  in  which  the  aims  were  to  compare  weight  and/or
eight  gain,  without  relationship  with  pulmonary  function,
nd  those  in  which  the  aims  were  to  describe  CF  only.
In  the  ﬁrst  search,  a  total  of  104  articles  were  found.
y  evaluating  titles  and  abstracts,  the  following  recupera-
ion  criteria  for  complete  articles  were:  studies  of  cohort,
ongitudinal,  cross-sectional,  descriptive  and  prospective,
hich  results  evaluated  the  relationship  among  pulmonary
unction  and  growth  parameters  in  CF  patients,  excluding
hose  which,  despite  of  appearing  in  the  search  results,  did
ot  address  the  subject  under  this  point  of  view.  In  this
tage,  27  papers  were  screened.  The  review  was  concluded
ith  the  reading  of  the  complete  articles,  and,  in  the  ﬁnal
anuscript,  seven  articles  were  included,12--18 all  of  them  in
nglish  (Fig.  1;  Tables  1  and  2).
ata synthesis total  of  12,455  patients  were  assessed.  Considering  the
tart  up  period  of  each  study,  the  age  range  of  the  patients
as  0--15.3  years  old.  According  to  the  study  design,  one
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sFigure  1  Method  of  research,  screening,  exclusion  and  inclusio
were found.
was  a  cohort  study,12 four  were  longitudinal  studies13--15,17
and  two  were  prospective  studies.16,18
The  selected  studies  used  several  growth  and  nutritional
parameters.  Among  the  nutritional  and  growth  parameters,
Body  Mass  Index  (BMI)  was  evaluated  in  ﬁve  studies,12,14--16,18
height  alone  was  evaluated  in  two  studies,13,15 height  gain
was  evaluated  in  two  studies,13,15 Weight  For  Age  (WFA)  was
evaluated  in  two  studies,14,18 Height  For  Age  (HFA)  was  eval-
uated  in  two  studies.14,16 The  remaining  parameters  were
evaluated  each  one  in  one  study:  weight  alone,14 percent
of  height-appropriate  Body  Weight  (%haBW),12 percentage
of  the  Ideal  Body  Weight  (%IBW),12 Height  for  Age  Z-score
(HAZ),12 Weight  for  Age  Z-score  (WAZ),12 Height-For-Age
adjusted  for  Target  Height  (HFA/TH),17 Weight-For-Length
and  BMI  percentiles  (WFL-BMI)18 (Tables  1  and  2).
All  studies  used  Forced  Expiratory  Volume  in  1  second
(FEV1  or  FEV1%  predicted)  as  a  measure  for  pulmonary  func-
tion  and  only  one  used  forced  vital  capacity.14
Six  studies  assessed  the  relationship  of  growth  and  nutri-
tional  parameters  with  pulmonary  function12--14,16--18 and  only
one  study  assessed  the  relationship  of  growth  alone  with
pulmonary  function.15
Main results
Zemel  et  al.12 studied  a  large  sample  (968  children)  from
multiple  care  centers  across  the  United  States  during  a  4
year  period.  During  the  ﬁrst  3  years  of  follow-up,  the  female
patients  declined  in  HAZ,  whereas  male  patients  increased
HAZ.  Both  groups  declined  in  this  same  parameter  in  the
last  year.  There  were  differences  in  the  pattern  of  longitu-
dinal  change  in  FEV1%,  and  the  rate  of  decline  was  less  in
male  patients.  The  authors  found  that  HAZ  was  positively
p
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nd  signiﬁcantly  associated  with  FEV1%,  as  were  WAZ  and
haBW.
Konstan  et  al.13 examined,  in  931  patients,  the  relative
ole  of  growth  and  nutritional  status  and  the  clinical  evi-
ence  of  lung  disease  from  age  3--6  years  in  determining
ulmonary  function  at  6 years  of  age.  The  results  showed
hat  mean  WFA  and  HFA  at  both  ages  3  and  6  years  were
elow  the  50th  percentile  for  healthy  children.  The  pres-
nce  of  signs  and  symptoms  of  lung  disease  at  age  3  was
nly  weakly  associated  with  growth  and  nutritional  cate-
ories  in  this  same  age.  However,  patients  with  lower  growth
nd  nutritional  indexes  at  age  3  had  lower  pulmonary  func-
ion  at  age  6,  and  this  was  evident  for  WFA  and  HFA,  in  which
he  differences  in  the  percent  predicted  lung  function  val-
es  reached  15  and  12  points  for  the  lowest  and  high  WFA
nd  HFA  categories,  respectively.
Peterson  et  al.14 prospectively  examined  data  of  319  chil-
ren  from  ages  6--8  years.  Total  weight  change  (kg/month)
etween  the  child’s  ﬁrst  and  last  visits  was  examined  as  a
arker  of  cumulative  growth  during  the  2  year  period.  In
epeated  measures  regression  analysis,  FEV1  values  did  not
ary  signiﬁcantly  by  height  change  within  patients  with  high
r  low  weight  change.  Neither  the  height  nor  change  in  the
eight  from  ﬁrst  observation  were  signiﬁcantly  associated
ith  FEV1  values,  but  children  who  had  a  steady  weight  gain
ended  to  experience  greater  increases  in  FEV1  than  those
ho  lose  weight.
Assael  et  al.15 followed  163  patients  in  order  to  evalu-
te  the  relationship  between  linear  growth  and  lung  disease
everity.  This  study  showed  a  progressive  loss  of  FEV1  in
atients  with  mild  and  severe  lung  disease.  In  patients  with
evere  disease,  the  pre-pubertal  take-off  and  peak  occurred
ater  and  at  slightly  lower  velocity  compared  to  patients
ith  mild  disease.  Pubertal  peak  of  severe  patients  occured
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Table  1  Description  of  the  studies  included  in  the  systematic  review  published  before  2010,  distributed  by  authorship,  design,  location,  objective  or  hypothesis,  main  variables
studied and  main  ﬁndings.
Study  Design  Location  Objective  Variables  analyzed  Main  ﬁndings
Zemel  et  al.  (2000)12 Cohort  Philadelphia,  United  States  To  determine  the
relationship  among
growth,  nutritional
status  and  pulmonary
function  in  cystic  ﬁbrosis
patients  over  a  4  year
period
Forced  Expiratory
Volume  in  1
second
(Percentage  of
predicted),  Height
for  Age  Z  score,
Weight  for  Age  Z
score,  Body  Mass
Index,  percentage
of
height-appropriate
Body  Weight
The  Z-scores  for  weight
and  percentage  of
height-appropriate  Body
Weight  were  associated
with  longitudinal
changes  in  FEV1%  after
adjustments  was  done
for  hospitalizations
Konstan et  al.  (2003)13 Longitudinal  Multicentric  (United  States  and  Canada)  To  examine  the  relative
roles  of  growth  and
nutritional  status  and
clinical  evidence  of  lung
disease  from  age  3  to  6
years  in  determining
pulmonary  function  at
age  6  years
Weight  For  Age,
Height  for  Age,
Percentage  of
Ideal  Body  Weight,
Body  Mass  Index,
Forced  Expiratory
Volume  in  1
second,  Forced
Vital  Capacity
Weight  For  Age,  Height
For  Age  and  Percentage
of Ideal  Body  Weight
were  poorly  associated
with  lung  disease  at  age
3,  but  all  were  strongly
associated  with
pulmonary  function  at
age  six
Peterson et  al.  (2003)14 Longitudinal  Minneapolis,  United  States  To  evaluate  how  the
weight  gain  pattern  of
children  with  cystic
ﬁbrosis  affects  their
pulmonary  function
development
Baseline  height;
height  gain;
weight  gain
Children  who  had  steady
weight  gain  tended  to
experience  greater
increases  in  Forced
Expiratory  Volume  in  1
second  than  children
who  experienced
periodic  losses  in  weight
Assael et  al.  (2009)15 Longitudinal  Veneto  Region,  Italy  To  ﬁnd  a  correlation
between  growth  and
lung  disease  severity
through  childhood
Forced  Expiratory
Volume  in  1
second,  height
gain
Lung  disease  severity
correlated  with  delayed
prepubertal  and
pubertal  growth
milestones.  Peak  height
velocities  were  reduced
in  relation  to  the
severity  of  the  disease
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Table  2  Description  of  the  studies  included  in  the  systematic  review  published  after  2010,  distributed  by  authorship,  design,  location,  objective  or  hypothesis,  main  variables
studied and  main  ﬁndings.
Study  Design  Location  Objective  Variables  analyzed Main  ﬁndings
Yen  et  al.  (2013)16 Prospective Multicentric  (United  States) To  evaluate  the
relationship  between
nutritional  status  early
in life  and  the  timing
and  velocity  of  height
growth,  lung  function,
complications  of  cystic
ﬁbrosis,  and  survival
Body  Mass  Index,
Forced  Expiratory
Volume  in  1
second,  Height  for
Age  Percentile,
Weight  for  Age
Percentile
Weight  for  Age
Percentile>10%  at  age  4
was  associated  with
better  lung  function
from  ages  6--18.  By  age
18, patients  with  an  age
4  WAP>50%  suffered
fewer  acute  pulmonary
exacerbations
Woestenenk et  al.  (2014)17 Longitudinal  Utrecht,  The  Netherlands To  measure  the  weight
and  height  of  children
with  cystic  ﬁbrosis  from
2 to  10  years  old  and  to
investigate  the
relationship  between
these  parameters  and
Forced  Expiratory
Volume  in  1  second
beginning  at  6  years  old
Forced  Expiratory
Volume  in  1
second,  Weight
For  Age,  Height
For  Age,  Height
For  Age  (adjusted
for  Target  Height),
Weight  For  Height
The  yearly  decline  in
Forced  Expiratory
Volume  in  1  second  was
signiﬁcantly  slowed  in
children  who  gained
weight
Sanders et  al.  (2015)18 Prospective  Multicentric  (United  States)  To  characterize  early  life
growth  trajectories  and
to  determine  if  these
trajectories  are
associated  with  Forced
Expiratory  Volume  in  1
second  at  ages  6--7  years
Forced  Expiratory
Volume  in  1
second
(Percentage  of
predicted),  Weight
For  Length,  Body
Mass  Index
Subjects  with  Weight  For
Length  and  Body  Mass
Index  always  >50th
percentile  had  the
highest  Forced
Expiratory  Volume  in  1
second  (Percentage  of
predicted)  predicted  at
age  6--7  years,
signiﬁcantly  higher  than
subjects  whose  Weight
For  Length  and  Body
Mass  Index  was  stable  or
decreased  >10
percentile  points
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bout  8  months  later  than  that  of  mild  patients.  Their  peak
elocity  was  lower  by  1.3cm/year  (vs.  mild  disease)  and
.0cm/year  (vs.  healthy  subjects).  When  age,  height  and
eight  velocity  at  all  the  four  growth  milestones  were  con-
idered  as  a  whole,  the  differences  between  patients  with
ild  and  severe  disease  were  highly  signiﬁcant.
Yen  et  al.,16 in  a  prospective  observational  study,  evalu-
ted  3,142  CF  patients  and  found  that  FEV1%  was  lower  in
he  group  of  patients  with  WAP<10%  at  age  4  years  than  all
ther  WAP  groups,  never  reaching  a  FEV1>80%  throughout
he  study  period.  This  study  also  found  that  patients  in  the
ighest  weight  and  height  percentiles  at  age  4  had  fewer
ulmonary  exacerbations,  spent  fewer  days  in  the  hospital,
nd  had  better  survival  at  18  years  of  age.
Woestenenk  et  al.,17 studying  156  children  in  a mean
eriod  of  7.4  years,  did  not  ﬁnd  correlation  between  FEV1%
nd  either  weight  or  height,  in  a  ﬁrst  cross  sectional  analy-
is.  However,  regardless  of  their  initial  WFA  or  WFH  category,
hildren  who  increased  in  weight  had  minor  declines  in
EV1%  predicted  from  6  to  10  years  old.  The  decline  in
EV1%  slowed  by  1.8%  and  1.9%,  respectively,  for  each  unit
f  increase  in  WFA  and  WFH.  The  study  did  not  ﬁnd  any
ssociation  between  FEV1 and  either  HFA  or  HFA/TH.
Sanders  et  al.18 prospectively  studied  6,805  patients  in
he  Cystic  Fibrosis  Foundation  Patient  Registry.  Children  with
F  born  between  1994  and  2005  followed  from  age  ≤2
hrough  7  years  were  assessed  according  to  changes  in  annu-
lized  WFL  percentiles  between  ages  0  and  2  years  and  BMI
ercentiles  between  ages  2  and  6  years.  The  results  of  a
ultivariable  linear  regression  model  showed  that  subjects
ith  WFL-BMI  always  >50th  percentile  had  the  highest  FEV1%
redicted  at  age  6--7  years,  signiﬁcantly  higher  than  sub-
ects  whose  WFL-BMI  was  stable  or  decreased  >10  percentile
oints.
iscussion
tudies  for  the  management  of  CF  patients  have  been  con-
ributing  for  the  advance  in  the  multidisciplinary  care,
iming  at  the  best  treatment  of  this  disease.  Despite
hese  improvements,  pulmonary  insufﬁciency  remains  as
he  main  cause  of  death  in  CF  and  there  are  strong  asso-
iations  between  growth  and  nutritional  indices  and  lung
unction.19 However,  most  studies  reporting  these  evidences
re  cross-sectional,  with  few  evidences  to  support  associa-
ion  between  longitudinal  changes  in  growth  and  nutrition
ith  changes  in  lung  function  through  life.
The  study  conducted  by  Assael  et  al.15 was  the  ﬁrst  one
o  demonstrate  a  clear  association  between  early  growth
vents  and  lung  function  in  CF  patients.  This  study  showed
 progressive  loss  of  FEV1  in  patients  with  mild  and  severe
ung  disease.  In  patients  with  severe  lung  disease,  the  pre-
ubertal  take-off  and  peak  occurred  later  and  at  slightly
ower  velocity  compared  to  patients  with  mild  disease.
ubertal  peak  of  severe  patients  occurred  about  8  months
ater  than  that  of  mild  patients.  Their  peak  velocity  was
ower  by  1.3cm/year  (vs.  mild  disease)  and  2.0cm/year  (vs.
ealthy  subjects).  When  age,  height  and  height  velocity  at
ll  the  four  growth  milestones  were  considered  as  a  whole,
he  differences  between  patients  with  mild  and  severe
isease  were  highly  signiﬁcant.  The  main  ﬁnding  of  this
a
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tudy  is  that  low  height  velocity  is  an  early  manifestation
f  lung  disease  severity  in  CF.
Two  studies14,17 did  not  ﬁnd  associations  between  changes
n  height  and  changes  in  FEV1,  but  these  studies  were  con-
ucted  in  shorter  periods  of  time,  and,  differently  from  two
tudies  previously  mentioned,15,16 their  analyses  included
hildren  whose  ages  ranged  from  2  to  10  years  old.  Thus,
he  inﬂuence  of  growth  spurts  could  not  be  assessed.  How-
ver,  both  studies  point  to  an  association  between  weight
ain  and  better  lung  function.
Three  studies12,13,18 reported  that  the  improvement  of
oth  growth  and  clinical  parameters  in  early  life  was  asso-
iated  with  a  better  lung  function  2--5  years  later.  Thus,
t  is  suggested  that  growth  and  nutritional  status  in  child-
ood  may  be  strong  predictors  of  the  severity  of  lung  disease
ater  in  life,  which  is  reinforced  by  Yen  et  al.,16 who  showed
hat  patients  in  the  highest  weight  and  height  percentiles
t  age  4  years  had  fewer  pulmonary  exacerbations,  spent
ewer  days  in  the  hospital,  and  had  better  survival  at  age
8  years.
Pulmonary  function  abnormalities,  including  decreased
eak  ﬂow  and  lower  vital  capacity,  forced  vital  capac-
ty,  and  forced  expiratory  ﬂow,  occur  in  other  conditions
n  which  children  are  malnourished  and  have  stunted
rowth.20--23 Nutritional  interventions  with  malnourished
atients  showed  that  enhanced  caloric  intake  resulted  in
ncreased  weight  and  height  gain  velocities  and  improve-
ents  in  other  nutritional  status  measures,  besides
eduction  in  cases  of  pulmonary  infections  or  slower  deteri-
ration  in  pulmonary  function.10,24--26 Growth  and  nutrition
re  two  intimately  linked  characteristics,  so,  since  better
utrition  is  associated  to  better  lung  function  in  CF,  main-
aining  a healthy  nutritional  status  is  important  not  only
or  nutrition  and  growth,  but  for  lung  function  as  well.27
tephenson  et  al.28 studied  a  cohort  of  909  CF  patients.
ubjects  in  the  overweight  and  obese  categories  were  older
nd  presented  better  lung  function.  Within  the  underweight
roup,  a  10%  increase  in  BMI  resulted  in  a  4%  relative  increase
n  FEV1  and  individuals  with  a  BMI  in  the  adequate  range
ad  a  5%  relative  increase  in  FEV1.  This  was  the  ﬁrst  study
o  characterize  changes  in  nutritional  status  overt  time  and
o  quantify  the  relation  between  nutrition  and  lung  func-
ion  across  the  spectrum  of  BMI  categories.  Regarding  to
mprovement  in  growth,  the  evidences  for  clinical  trials  are
lso  limited.  Growth  hormone  therapy  does  not  seem  to
mprove  lung  function  at  a  signiﬁcant  level.29
In  summary,  the  studies  highlight  the  importance  of  opti-
izing  growth  and  nutritional  status  in  CF  patients  by  an
ggressive  nutritional  intervention,  and  also  by  treatment  of
ulmonary  disease,  even  in  those  with  milder  pulmonary  dis-
ase.  However,  the  relationship  of  longitudinal  growth  and
ung  function  in  CF  is  still  unclear  and  must  be  better  inves-
igated.  Controlled  trials  with  therapies  focused  on  the  pul-
onary  disease  are  necessary  to  investigate  its  relationship
ith  growth  and  nutritional  status.  Given  the  deterioration
hat  lungs  suffer  with  time  in  CF,  long  term  studies  are  impor-
ant  to  better  characterize  these  parameters  and  to  identify
hich  factors  are  more  deeply  involved  in  this  process,  thus,
ppropriate  interventions  may  be  implemented.  More  sen-
itive  measures  for  lung  function,  such  as  lung  clearance
ndex,  are  also  necessary  to  better  diagnose  the  severity  of
ung  disease,  mainly  for  the  preschool  age  range.30 There
onar
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are  about  2000  mutations  of  the  CFTR  gene,  distributed
among  six  classes.  Thus,  studies  of  association  among  varia-
bles  must,  in  the  future,  be  structured  for  mutation  classes
that  conﬁgure  a  more  severe  disease  (classes  I,  II  and  III).
The  higher  facility  of  access  to  medicines,  attendance  at
reference  centers,  neonatal  screening,  early  treatment  for
Pseudomonas  aeruginosa  infection,  early  intake  of  pancre-
atic  enzymes,  knowledge  of  polymorphisms  and  differential
follow-up  in  adolescence  and  adulthood  (mainly  for  the
female  gender)  are  factors  that  may  equilibrate  and  mod-
ify  the  natural  history  of  CF  with  regard  to  the  pulmonary
function  decline,  growth  and  nutrition  of  these  patients.
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